complex and thus probably is not as good a sulphydryl agent as penicillamine. Dr H E Amos (Carshalton): A number of speakers have referred to hapten-carrier relationships in connection with the mechanism of adverse responses to penicillamine, but what is the hapten and what is the carrier? The known data could be explained by considering that the carrier is penicillamine and the hapten is part of the tissue macromolecule. The initiating stimulus for the immune response would be the foreign moiety of the complexes, i.e. penicillamine, and this would generate antibodies against the hapten. Antipenicillamine antibodies have been detected, and there are a number of reports indicating that autoantibodies are also produced. The lathyrogenic effect of penicillamine may be important in the formation of hapten-carrier complexes, particularly if they break loose from fixed sites and circulate in the blood. Dr Jaffe: It is a perfectly plausible theory, particularly in view of the lathyrogenic properties of the drug which could cause it to bind to collagen, denaturing it in the process. Dr Jayson once took me up on this because he felt that the different collagens would not react biochemically with the drug except for dermal collagen. Even that could be a good hapten source because there is plenty of skin. Beyond that, it is not possible to say anything other than that it is a plausible suggestion. In reply to Dr Jellum's point about the gold/penicillamine identity, he said more in his 10 minutes than I did when I spoke for 25 minutes on the subject recently.
I would like to suggest that there may be a much easier way to answer the question he raises than doing a controlled trial. We throw out the term 'controlled trial' rather freely, but it is quite difficult to do such trials. Gold and penicillamine share one thing in common; that is their striking effect on rheumatoid factor (RF) titre. I suggest that 3 or 4 patients, with a reasonably good titre, be given thiomalate in an open study. Their clinical changes would be of secondary importance, but careful monitoring of RF titres would be performed. A significant fall in RF titre induced by thiomalate after 4-6 months would be very provocative and merit a full clinical trial. In 1963 I had occasion to do almost the identical experiment using thioglucose, which is the moiety of Solganal, kindly prepared for me by the Schering Corporation. I gave 1 g a day for 4 months to one patient. Nothing happened clinically or to the RF titre, but that should not dissuade you from going ahead.
Dr J Glyn (London): I wonder whether that experiment has already been done in the sense that in the Empire Rheumatism Council gold trial, to which Dr Dixon has referred, the controls were on the thiomalate. Is that correct ? Dr A G S Hill (Stoke Mandeville): The controls were on a dose of Myocrisin which was onethousandth of the dose which was used in the 'treated' series, i.e. a course totalling I mg instead of 1000 mg.
Concluding Remarks by Dr A G S Hill (Stoke Mandeville)
The speakers have given their material with such clarity that it would be presumptuous to try to sum up. It gives me the opportunity, however, of saying a few things which are relevant, if not amounting to a formal summing up.
First, an impression which I have had for a long time about penicillamine has been reinforced by this meeting. It is that one does not do clinical trials and experiments with this agent, but has an affaire with it. I would not for a moment suggest that this in any way detracts from the scientifically critical approach that all of us have to it, but it is intriguing to observe its emotional effect. We could enlarge upon this by looking at the delightful programme cover depicting Pandora. Various other characteristics were recognized in speeches last night: she can be fickle, rewarding, even frustrating. This is why the compound is such an excellent centrepiece for a meeting like this and why it has produced such a feeling of community among the people who have dealt with it from all aspects.
I wonder what Dr Walshe really thinks of the way rheumatologists have seized upon penicillamine. He introduced a wonderfully precise key which fitted the lock of a very rare disease. Rheumatologists have adopted it without any clear idea of how it works in their field, and have used it in one of the commonest diseases in the world. We have treated it as a sort of master key which will unlock a lot of doors, but we do not know which one it is unlocking.
